Historical record - last NADAC publication: 6/19/2024

Product Information

VOSEVI 400-100-100 MG TABLET is a brand product labeled by Gilead Sciences, Inc., priced at $858.6884 per EA under NDC 61958240101. Its NADAC has been published 61 times since Apr 17, 2024.

VOSEVI 400-100-100 MG TABLET

SOFOSBUVIR, VELPATASVIR, and VOXILAPREVIR

$858.6884per EA

Strength

400; 100; 100 mg/1; mg/1; mg/1

Manufacturer

Gilead Sciences, Inc.

NDC

61958240101

Classification

Brand

Dosage Form

TABLET, FILM COATED

Route

ORAL

Last Updated

6/19/2024

Active Ingredients

SOFOSBUVIR; VELPATASVIR; VOXILAPREVIR

Approval Type

New Drug (NDA)

FDA Application

NDA209195

On Market Since

7/18/2017

Pharmacological Classes

Breast Cancer Resistance Protein Inhibitors

HCV NS3/4A Protease Inhibitors

Hepatitis C Virus NS3/4A Protease Inhibitor

Hepatitis C Virus NS5A Inhibitor

Hepatitis C Virus Nucleotide Analog NS5B Polymerase Inhibitor

Organic Anion Transporting Polypeptide 1B1 Inhibitors

Organic Anion Transporting Polypeptide 1B3 Inhibitors

Organic Anion Transporting Polypeptide 2B1 Inhibitors

P-Glycoprotein Inhibitors

RNA Replicase Inhibitors

Price Statistics

The NADAC for VOSEVI 400-100-100 MG TABLET has been published 61 times since Apr 17, 2024, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.

Current price	$858.6884 per EA
All-time high	$858.6884 (Jun 11, 2025)
All-time low	$858.6884 (Apr 17, 2024)
Median price	$858.6884
Average price	$858.6884
Largest weekly change	0.0% (Apr 24, 2024)
Weeks tracked	61
Tracking since	Apr 17, 2024

Price History

0.0%

N/A

All

0.0%

Generic Alternatives

No other NADAC-published product shares this drug's active ingredient, strength, and dosage form. Compare the broader picture on the SOFOSBUVIR, VELPATASVIR, and VOXILAPREVIR market page.

Lowest-Cost Alternatives

No alternatives available

No alternatives found with the same active ingredient, strength, and dosage form.

Frequently asked questions

What is the NADAC price of VOSEVI 400-100-100 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for VOSEVI 400-100-100 MG TABLET, manufactured by Gilead Sciences, Inc., is $858.6884 per EA (NDC 61958240101), effective Jun 11, 2025.

How has the price of VOSEVI 400-100-100 MG TABLET changed over time?

Over the history we have for it, the NADAC for VOSEVI 400-100-100 MG TABLET has held within roughly two percent of its current level. It has been tracked across 61 weekly CMS publications since Apr 17, 2024.

What are the highest and lowest recorded NADAC prices for VOSEVI 400-100-100 MG TABLET?

Since Apr 17, 2024, the NADAC for VOSEVI 400-100-100 MG TABLET has ranged from a low of $858.6884 (Apr 17, 2024) to a high of $858.6884 (Jun 11, 2025), with a median of $858.6884 per EA.

Are there cheaper alternatives to VOSEVI 400-100-100 MG TABLET?

No other NADAC-published product currently shares the active ingredient, strength, and dosage form of VOSEVI 400-100-100 MG TABLET, so no direct lower-cost alternative is listed.